<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-292 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-292</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-292</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-248164281</p>
                <p><strong>Paper Title:</strong> Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR exon 20 and exon 21: a case report</p>
                <p><strong>Paper Abstract:</strong> Background Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for non-small cell lung cancer (NSCLC). The PIONEER study showed that 51.4% of unselected Asian patients with advanced lung adenocarcinoma have EGFR-sensitive mutations. EGFR mutations mainly occur in the first four [18â€“21] exons of the intracellular tyrosine kinase (TK) region. At present, there are more than 30 types of mutations in the TK region, including exon 19 deletion mutation (19Del) and exon 21 L858R mutation (L858R) which are the most common types of sensitive mutations, accounting for more than 90% of all EGFR mutations. About 10% of NSCLC patients with EGFR mutations are rare mutation types, including exon 18 point mutation (G719X), exon 20 point mutation (S768I), exon 19 point mutation (L747S), exon 21 point mutation (L833V), etc. About 1% of NSCLC patients have primary double mutations of EGFR. Case Description In this present study, we identified a 59-year-old female patient with no smoking history had double mutations in EGFR exon 20 R776S mutation and exon 21 L858R mutation by next-generation sequencing (NGS). Conclusions This observation may explore a new mechanism study for EGFR-TKIs and provide a new direction for clinical treatment of NSCLC.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e292.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e292.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIONEER Asian EGFR prevalence</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The PIONEER study (cited in this paper) reported that 51.4% of unselected Asian patients with advanced lung adenocarcinoma harbor EGFR-sensitive mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian (unselected Asian patients)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Asia</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>51.4% EGFR-sensitive mutations in unselected Asian patients with advanced lung adenocarcinoma (as reported by PIONEER; cited in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Paper notes that exon 19 deletions (19Del) and exon 21 L858R are the most common EGFR-sensitive mutations (together >90% of EGFR mutations); also mentions rare mutations including exon 18 point mutations (G719X), exon 20 point mutations (S768I), exon 19 point L747S, exon 21 point L833V, and that primary double mutations occur in ~1% of NSCLC patients.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>EGFR mutations are reported (within this paper's citations) to be common in 'never-smokers' (i.e., more frequent among never-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (advanced lung adenocarcinoma; PIONEER focus)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>General statement in paper: EGFR-mutated NSCLC shows higher response rate and longer median progression-free survival to EGFR-TKIs than to platinum-based chemotherapy; no ethnicity-specific response rates provided.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e292.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e292.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>This paper - Chinese case</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR exon 20 and exon 21: a case report</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-patient case (Chinese, female, never-smoker) with stage IA lung adenocarcinoma harboring co-occurring EGFR exon 21 L858R and exon 20 R776S mutations detected by NGS (MAF values reported).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Chinese</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>China (The Second Hospital of Dalian Medical University, Dalian)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>1</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>EGFR exon 21 L858R detected with mutant allele frequency (MAF) 6.3% (tissue); EGFR exon 20 R776S detected with MAF 4.7% (tissue); plasma testing did not detect these mutations. Tumor mutational burden (TMB) reported as 2.3 mutations per Mb.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>EGFR exon 21 L858R (classical sensitizing mutation) and EGFR exon 20 R776S (novel/rare co-mutation in this case).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Patient was a never-smoker (case-level observation); paper cites literature that EGFR mutations are more common in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Patient is female (case-level observation); paper does not perform an analysis of gender correlation.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Moderately differentiated adenocarcinoma (80% acinar, 20% mural), stage IA (T1cN0M0).</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>